|
941 |
Optimization and comparison of genomic DNA extraction from whole blood collected in PAXgene blood RNA tube using automated platforms
Enthalten in Clinical chemistry and laboratory medicine Bd. 64, 2026, Nr. 3: 600-608. 09 S.
|
|
|
|
942 |
Methodological evaluation and clinical interpretation of hs-cTnI and hs-cTnT variations: a reappraisal
Enthalten in Clinical chemistry and laboratory medicine Bd. 64, 2026, Nr. 3: 566-569. 04 S.
|
|
|
|
943 |
Comparison of the cardiac troponin I-cardiac troponin T-troponin C complex and cardiac troponin I and T in distinguishing myocardial infarction using a single sample at presentation
Enthalten in Clinical chemistry and laboratory medicine Bd. 64, 2026, Nr. 2: 505-512. 08 S.
|
|
|
|
944 |
EQALM recommendations for the analytical performance specifications for blood smear interpretation in hematology: a need for standardization
Enthalten in Clinical chemistry and laboratory medicine Bd. 64, 2026, Nr. 2: 479-488. 10 S.
|
|
|
|
945 |
Establishing reference intervals for high-sensitivity cardiac troponin T in neonates and infants
Enthalten in Clinical chemistry and laboratory medicine Bd. 64, 2026, Nr. 2: 454-459. 06 S.
|
|
|
|
946 |
Influence of remnant cholesterol on direct LDL and HDL cholesterol measurement accuracy
Enthalten in Clinical chemistry and laboratory medicine Bd. 64, 2026, Nr. 2: 432-444. 13 S.
|
|
|
|
947 |
Staining and serological characteristics of the AC-30 pattern in HEp-2 IIFA: a comparative study with AC-2 pattern
Enthalten in Clinical chemistry and laboratory medicine Bd. 64, 2026, Nr. 2: 401-409. 09 S.
|
|
|
|
948 |
Estimated waste generation from 1 million basic metabolic panels: a multisite U.S. study
Enthalten in Clinical chemistry and laboratory medicine Bd. 64, 2026, Nr. 2: 361-367. 07 S.
|
|
|
|
949 |
Requiem for the Passing–Bablok nonparametric regression in assessing the agreement between two measurement methods
Enthalten in Clinical chemistry and laboratory medicine Bd. 64, 2026, Nr. 2: 343-352. 10 S.
|
|
|
|
950 |
Failure Mode and Effects Analysis (FMEA) integrating quality indicators for risk assessment of the total testing process in human papillomavirus genotyping testing: a proactive risk analysis model for molecular diagnostics
Enthalten in Clinical chemistry and laboratory medicine Bd. 64, 2026, Nr. 2: 305-331. 27 S.
|
|
Administration
